The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 in mice) is followed by an accumulation of deletions, genome doubling, and the emergence of gains and amplifications.

HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia.

Brii Biosciences has disclosed prodrugs of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) reported to be useful for the treatment of HIV infection.

Blue Water Vaccines (BWV) will attempt to present monkeypox antigens within its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel monkeypox vaccine.

There is a need of better markers that reflect key mechanisms involved in diabetic kidney disease (DKD). In a new study, investigators have identified increased concentrations of neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a strong and independent predictor of progression to end-stage kidney disease (ESKD) in patients with diabetes.

Preclinical data has been reported for RCD-405, which is being developed by Arcede Pharma, a spin-out from Respiratorius AB, for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD).

Stinging nettle leaf has been used in traditional treatments for conditions such as lower urinary tract symptoms, possibly through a smooth muscle relaxant effect. Monash University scientists have investigated the mechanism in studies in vitro and in vivo.

The U.S. Department of Defense (DoD) is awarding Codagenix USD 4.4 million for further development of its next-generation tetravalent dengue vaccine candidate CodaVax-DENV.

Hepatocellular carcinoma (HCC) still remains a global health challenge as it shows genetic heterogeneity and limited therapy response. In a new study, the cellular responses in HCC that accompany the nearly universal repression of urea cycle enzymes and consequent arginine auxotrophy were investigated, since previous findings demonstrated that that HCC consistently represses urea cycle gene expression and thus become auxotrophic for exogenous arginine becoming severe disease.

Merck & Co. is to collaborate with Orna Therapeutics on discovery, development and commercialization in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.